DRMA
Dermata Therapeutics, Inc.
$1.34
+0.00 (+0.00%)
At close · Jul 6
Market Cap
$5.39M
Shares
4,022,143
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$1.34
Open$1.33
Day$1.28–1.37
52W$1.10–8.00
Avg vol 30d82K
Short int93K · 2.3% float · 1.6d
Short vol23%
Last earningsMay 13, 2026
DataAug 2021–Jul 2026
Filing10-Q · May 13
Equibles Rating
blended score · not investment advice
Overall
Buy
Technical · trend & momentum
Neutral
◦
50 / 200-day cross
no cross
−
Price vs 200-day avg
−40% below
+
Price vs 50-day avg
+7% above
◦
RSI (14)
56 · neutral
+
MACD trend
positive
−
52-week position
3% · near low
Sentiment · smart money
Neutral
◦
Trend (MA cross)
50d $1 › 200d $2 — 200d above 50d
◦
Institutional flow
0% holders QoQ · +4 funds added
−
Insider flow
Net -$13 over 90 days · 100% sells
+
Short interest
2.31% of float · ▼ -3.7% MoM · 1.6 days cover
◦
Volume signal
Volume near normal
◦
Institution breadth
7 holders — 13F breadth
Fundamentals
Excellent
+
EPS growth
+90% Y/Y
+
Balance sheet
net cash $7.5M
Blended from price, positioning & fundamentals · daily-close · not investment advice.
Up next
Next earnings call
Aug 13, 2026
Est · unconfirmed
· in 5 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 13, 2026
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
no cross
Neutral
Price vs 200-day avg
−40% below
Bearish
Price vs 50-day avg
+7% above
Bullish
RSI (14)
56 · neutral
Neutral
MACD trend
positive
Bullish
52-week position
3% · near low
Bearish
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $1 › 200d $2 — 200d above 50d
Institutional flow
Flat
0% holders QoQ · +4 funds added
Insider flow
Distributing
Net -$13 over 90 days · 100% sells
Short interest
Falling
2.31% of float · ▼ -3.7% MoM · 1.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
7 holders — 13F breadth
Price context
position in its 52-week range
52-wk low $1
Now $1 · 3%
52-wk high $8
vs 200-day avg -40%
vs 50-day avg +7%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
DRMA
this stock
Dermata Therapeutics, Inc.
|
$5.39M | -42.2% | — | — | 2.3% |
|
AKTX
Akari Therapeutics Plc
|
$998.08B | -5.7% | — | — | 0.0% |
|
ONC
BeOne Medicines Ltd.
|
$488.96B | +1.9% | +22179.2% | 995.1 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$134.41B | +16.8% | +46.2% | 31.4 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$69.33B | -15.7% | +20.8% | 16.1 | 3.2% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| DRMA | +3.9% | +7.2% | -35.6% | +3.9% | -42.2% |
| SPY | +3.1% | -0.8% | +8.2% | +0.6% | +10.2% |
| vs SPY | +0.8% | +8.0% | -43.8% | +3.3% | -52.4% |